Journals / Retina-Vitreus / 2009 / Cilt: 17 - Sayı: 3

Optic atrophy secondary to vigabatrin; evaluation by OCT

Vigabatrin kullanımına bağlı gelişen optik atrofi; OKT ile değerlendirme

Pages
213–216
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper we report two cases with optic neuropathy secondary to Vigabatrin use and associated visual field defects and also Optic Coherence Tomography detected RNFL loss.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Vigabatrin, a GABA (gama amino butyric acid) transaminase enzyme inhibitor, used as an antiepileptic agent, may result in visual field loss that may lead to tunnel vision at the end.
📊
Key Findings & Data:It may also cause optic neuropathy and damage to the retina nerve fiber layer (RNFL).
💡
Conclusion & Impact:In this paper we report two cases with optic neuropathy secondary to Vigabatrin use and associated visual field defects and also Optic Coherence Tomography detected RNFL loss.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Görme keskinliği · Optik sinir hastalıkları · Orta yaşlı

Abstract

Vigabatrin, a GABA (gama amino butyric acid) transaminase enzyme inhibitor, used as an antiepileptic agent, may result in visual field loss that may lead to tunnel vision at the end. It may also cause optic neuropathy and damage to the retina nerve fiber layer (RNFL). In this paper we report two cases with optic neuropathy secondary to Vigabatrin use and associated visual field defects and also Optic Coherence Tomography detected RNFL loss.

Özet

Gaba amino bütirik asit (GABA) transaminaz enzim inhibitörü antiepileptik ajan Vigabatrin, tünel vizyona kadar ilerleyebilen ciddi görme alanı daralmasına, retina sinir lifi tabakasında (RSLT) harabiyete ve optik nöropatiye neden olabilir. Bu çalışmada Vigabatrin kullanımına bağlı görme alanı daralmaları, Optik Koherens Tomografi (OKT) ile tespit edilmiş RSLT kaybı ve optik nöropatileri olan iki olgu sunulmuştur.

🔖

Cite This Article

SALAR, S., ÖZDÖKER, L. T., AKÇAKAYA, A. A., YAYLALI, A. S., ERBİL, H. H. (2009). Optic atrophy secondary to vigabatrin; evaluation by OCT. Retina-Vitreus, Cilt: 17 - Sayı: 3, 213–216. https://ajindex.com/articles/308086

References (17)

  1. Kalviainen R, Nousiainen I, Mantyjarvi M, et al.: Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology. 1999;53:922-926
  2. Acaroğlu Gölge, Güven Alev, Köse Gülşen, ve ark.: Çocukluk çağı epilepsisinde Vigabatrin ve görme alanı. MN Oftalmol, 2004,11:243-247
  3. Newman WD, Tocher K, Acheson JF.: Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye. 2002;16:567-571
  4. Daneshvar H, Racette L, Coupland SG, et al.: Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology. 1999;106:1792-1798
  5. Wild JM, Martinez C, Reinshagen G, Harding GF.: Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia. 1999;40:1784-1794
  6. Frisen L, Malmgren K.: Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand. 2003;81:466-473
  7. Buncic JR, Westall CA, Panton CM, et al.: Characteristic retinal atrophy with secondary “inverse” optic atrophy identifies vigabatrin toxicity in children. Ophthalmology. 2004;111:1935-1942
  8. Krauss GL, Johnson MA, Miller NR.: Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology. 1998;50:614-618
  9. Lawden MC, Eke T, Degg C, et al.: Visual field defects associated with vigabatrin therapy J Neurol Neurosurg Psychiatry. 1999;67:716-722
  10. Miller NR, Johnson MA, Paul SR, et al.: Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology. 1999 10;53:2082-2087
  11. Hilton EJ, Cubbidge RP, Hosking SL, et al.: Patients treated with vigabatrin exhibit central visual function loss. Epilepsia. 2002;43:1351-1359
  12. Nousiainen I, Kalviainen R, Mantyjarvi M.: Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. Ophthalmology. 2000;107:884-888
  13. Ozkul Y, Gurler B, Uckardes A.: Visual functions in epilepsy patients on valproate monotherapy. J Clin Neurosci. 2002;9:247-250
  14. Fledelius HC.: Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal. Acta Ophthalmol Scand. 2003;81:41-46
  15. Ben-Menachem E.: Vigabatrin. Epilepsia. 1995;36:95-104
  16. Kinirons P, Cavalleri GL, O’Rourke D, et al.: Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia. 2006;47:311-317
  17. Rebolleda G, García Pérez JL, Muñoz Negrete FJ, et al.: Vigaba